Application of human interferon containing pharmaceutical composition in preparation of medicine for preventing and treating virus infection of respiratory tract

A technology of recombinant human interferon and composition, which is applied in the field of medicine and achieves the effect of being beneficial to use and having less side effects

Inactive Publication Date: 2012-11-14
北京金迪克生物技术有限责任公司 +1
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, α, β, and γ have been studied more and used in clinical treatment; the clinical application value of other types of interferon is still under study

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of human interferon containing pharmaceutical composition in preparation of medicine for preventing and treating virus infection of respiratory tract
  • Application of human interferon containing pharmaceutical composition in preparation of medicine for preventing and treating virus infection of respiratory tract
  • Application of human interferon containing pharmaceutical composition in preparation of medicine for preventing and treating virus infection of respiratory tract

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0078] According to the method on pharmaceutics, prepare the spray, the volume of each bottle is 3.65 milliliters, wherein the active content of recombinant human interferon-α2b (Beijing Yuance Pharmaceutical Co., Ltd.) is 3,000,000 IU / ml, and the human albumin content is 0.5 %, the content of benzyl alcohol is 0.5%, the content of polysaccharide is 0.1%, and the concentration of phosphate buffer is 20mmol / L.

[0079] Each bottle of the product in this embodiment is 3 million IU / mL*3.65mL, and one preventive treatment course is 1 bottle, which is used for 3-5 days, which not only ensures the effective dose of interferon for local use, but also limits the dosage.

[0080] Tests were carried out on animals, and its irritation to mucous membranes and skin lesions was similar to that of normal saline, and no serious side effects were found. Compared with the U.S. IntronA powder injection, its side effects were moderate, while the side effects of the product of this example were neg...

Embodiment 2

[0083] According to the preparation method of the injection, add recombinant human interferon-α1a (Beijing Yuance Pharmaceutical Co., Ltd.) to a phosphate buffer solution with a pH of 7, so that the active content of the interferon is 1 million IU / mL, and add benzyl alcohol as a preservative , The weight content is 0.5%.

Embodiment 3

[0085] With reference to the method of Example 2, the obtained injection was divided into vials, 1.5 milliliters per bottle, and freeze-dried to obtain a freeze-dried powder injection.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
weightaaaaaaaaaa
Login to view more

Abstract

The invention relates to a medicine compound with interferon. Wherein, said compound can be used to prepare the medicine that prevents and resists virus infection of respiratory tract. Said compound contains interferon and other auxiliary materials. Wherein, said interferon can be alpha2b, alpha1b, beta, Omega, k, lambada, epsilon and other I type; said auxiliary materials contains protector andbaffle solution; and said interferon can be recombined interferon or / and the ones made by other methods; the auxiliary materials can be acidic buffer, protein, manna sugar, polyose, and benzoic alcohol to realize baffle, stabilize and corrosion-resistant functions.

Description

Technical field: [0001] The invention relates to the application of a pharmaceutical composition containing human interferon in the preparation of medicines for preventing and / or treating respiratory viral infection diseases, and belongs to the field of medicine. Background technique: [0002] Interferon (interferons, IFNs) is a class of proteins that have broad-spectrum anti-virus, anti-cell division, immunoregulatory activities and affect cell metabolism, growth and differentiation in different ways at least in the same kind of cells. New synthesis of RNA and protein. It is an important class of cytokines. After nearly 30 years of clinical research and application, it is an important broad-spectrum antiviral and antitumor drug. [0003] As far as we know, there are many types of human interferon: interferon-α, β, δ, γ, ε, κ, λ, τ and ω. Their main characteristics and possible clinical applications are shown in the following table: [0004] type main feature ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/21A61P31/12A61P31/16A61P31/22
Inventor 候云德
Owner 北京金迪克生物技术有限责任公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap